Lantern Pharma (LTRN) Operating Leases (2021 - 2026)

Lantern Pharma (LTRN) has reported Operating Leases for 6 consecutive years, with $59076.0 the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases changed 0.0% year-over-year to $59076.0; the trailing twelve-month figure through Mar 2026 stood at $59076.0 (changed 0.0% YoY), and the FY2025 full-year result was $78539.0, up 48.63% from the prior year.
• Operating Leases fell to $59076.0 in Q1 2026 per LTRN's latest filing, from $78539.0 in the prior quarter.
• Across five years, Operating Leases topped out at $291244.0 in Q3 2024 and bottomed at $13524.0 in Q2 2025.
• Historically, Operating Leases has averaged $116878.0 across 5 years, with a median of $99269.5 in 2022.
• The sharpest annual moves came in 2024 and 2025: Operating Leases surged 173.43% in 2024, then plunged 93.82% in 2025.
• Over 5 years, Operating Leases stood at $52890.0 in 2022, then rose by 16.27% to $61496.0 in 2023, then retreated by 14.07% to $52843.0 in 2024, then soared by 48.63% to $78539.0 in 2025, then declined by 24.78% to $59076.0 in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $59076.0, $78539.0, and $13524.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.